Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms - PubMed (original) (raw)

Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms

Amer Awad et al. Ther Adv Neurol Disord. 2009 Nov.

Abstract

For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone. Treating aggressive forms of RRMS and progressive disease forms of MS still presents a great challenge to neurologists. Intense immunosuppression has long been thought to be the only feasible therapeutic option. In patients with progressive forms of MS, lymphoid tissues have been detected in the central nervous system (CNS) that may play a critical role in perpetuating local inflammation. Agents that are currently approved for patients with MS have no or very limited bioavailability in the brain and spinal cord. In contrast, cyclophosphamide (CYC), an alkylating agent, penetrates the blood-brain barrier and CNS parenchyma well. However, while CYC has been used in clinical trials and off-label in clinical practice in patients with MS for over three decades, data on its efficacy in very heterogeneous groups of study patients have been conflicting. New myeloablative treatment paradigms with CYC may provide a therapeutic option in patients that do not respond to other agents. In this article we review the scientific rationale that led to the initial clinical trials with CYC. We will also outline the safety, tolerability and efficacy of CYC and provide neurologists with guidelines for its use in patients with MS and other inflammatory disorders of the CNS, including neuromyelitis optica (NMO). Finally, an outlook into relatively novel treatment approaches is provided.

Keywords: Cytoxan; MS; cyclophosphamide; immunology; multiple sclerosis; therapy; treatment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Balshov K.E., Smith D.R., Khoury S.J., Hafler D.A., Weinrer H.L. (1997) Increased interleukin-12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 94:599–603 - PMC - PubMed
    1. Blake D.A., Heller R.H., Hsu S.H., Schacter B.Z. (1976) Return of fertility in a patient with cyclophosphamide-induced azoospermia. Johns Hopkins Med J 139:20–22 - PubMed
    1. Blumenfeld Z. (2007) Gender difference: fertility preservation in young women but not in men exposed to gonadotoxic chemotherapy. Minerva Endocrinol 32:23–34 - PubMed
    1. CAMMS223 Trial InvestigatorsColes A.J., Compston D.A., Selmaj K.W., Lake S.L., Moran S., Margolin D.H.et al. (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786–1801 - PubMed
    1. Canadian Cooperative Multiple Sclerosis Study Group. (1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 337:441–446 - PubMed

LinkOut - more resources